MichaelMaitlandMDPhD

PubMed

• Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.
  Michael L. Maitland, J. Wilkerson, Sanja Karovic, Binsheng Zhao, Jessica Flynn, Mengxi Zhou, Patrick Hilden, Firas S. Ahmed, Laurent Dercle, Chaya S. Moskowitz, Ying T...> ;Clinical Cancer Research. 2020 Sep 28
• Cancer Clinical Investigators Should Converge with Pharmacometricians.
  Maitland, M. L., O'Cearbhaill, R. E., Gobburu, J.> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jun 30
• A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
  Amikar Sehdev, Theodore Karrison, Yuanyuan Zha, Linda Janisch, Michelle Turcich, Ezra E.W. Cohen, Michael L. Maitland, Blase N. Polite, Thomas F. Gajewski, Ravi Salgia...> ;Cancer Chemotherapy and Pharmacology. 2018 Jun 9
• Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study
  Laurent Claret, Christina Pentafragka, Sanja Karovic, Binsheng Zhao, Lawrence H. Schwartz, Michael L. Maitland, Rene Bruno> ;Cancer Chemotherapy and Pharmacology. 2018 Apr 26
• Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
  Michael L. Maitland, Sarina Anne Piha-Paul, Gerald S. Falchook, Razelle Kurzrock, Ly M. Nguyen, Linda Janisch, Sanja Karovic, Mark D. McKee, Elizabeth Hoening, Shekman...> ;British Journal of Cancer. 2018 Apr 1
• Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.
  Laurent Dercle, Dana E. Connors, Ying Tang, Stacey J. Adam, Mithat Gonen, Patrick Hilden, Sanja Karovic, Michael L. Maitland, Chaya S. Moskowitz, Gary J. Kelloff, Bins...> ;JCO clinical cancer informatics. 2018 Mar 2
• A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.
  Benjamin Wu, Lionel D. Lewis, R. D. Harvey, Erik Rasmussen, Erick Gamelin, Yu-Nien Sun, Greg Friberg, Jay L. Koyner, Afshin Dowlati, Michael L. Maitland> ;Clinical Pharmacology & Therapeutics. 2017 Aug 1
• PharmGKB summary: sorafenib pathways.
  Li Gong, Marilyn M. Giacomini, Craig P. Giacomini, Michael L. Maitland, Russ B. Altman, Teri E. Klein> ;Pharmacogenetics and Genomics. 2017 Jun 1
• 1 citations
  Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
  Abou-Alfa, G. K., Lewis, L. D., LoRusso, P., Maitland, M. L., Chandra, P., Cheeti, S., Colburn, D., Williams, S., Simmons, B., Graham, R. A.> ;Cancer chemotherapy and pharmacology. 2017 May 20
• 2 citations
  First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
  Forero, A., Bendell, J. C., Kumar, P., Janisch, L., Rosen, M., Wang, Q., Copigneaux, C., Desai, M., Senaldi, G., Maitland, M. L.> ;Investigational new drugs. 2017 Jan 5
• Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
  S Karovic, Eileen Shiuan, SQ Zhang, Hongyuan Cao, ML Maitland> ;Clinical and Translational Science. 2016 Oct 1
• Improving clinical trial design through quantitative pharmacology.
  Michael L. Maitland> ;Clinical advances in hematology & oncology. 2016 Aug 1
• 9 citations
  First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients...
  Li, T., LoRusso, P., Maitland, M. L., Ou, S. I., Bahceci, E., Ball, H. A., Park, J. W., Yuen, G., Tolcher, A. W.> ;Journal of hematology & oncology. 2016 Mar 12
• Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
  CH Li, Robert R. Bies, Yaning Wang, Sharma, Sanja Karovic, L Werk, Martin J. Edelman, Antonius A. Miller, Everett E. Vokes, Aytekin Oto, Mark J. Ratain, Lawrence H. Sc...> ;Clinical and Translational Science. 2016 Feb 1
• Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics
  Paul Geeleher, Andrey Loboda, Divya Lenkala, Fan Wang, Bonnie LaCroix, Sanja Karovic, J. Wang, Michael Nebozhyn, Michael Jon Chisamore, James Hardwick, Michael L. Mait...> ;Journal of the National Cancer Institute. 2015 Nov 1
• Serum C-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamic biomarkers in a trial of sequentially administered sunitinib and cilengitide
  Peter H. O'Donnell, Sanja Karovic, Theodore Karrison, Linda Janisch, Matthew R. Levine, Pamela Jo Harris, Blase N. Polite, Ezra E.W. Cohen, Gini F. Fleming, Mark J. Ra...> ;Clinical Cancer Research. 2015 Jul 21
• Identification of a Variant in KDR Associated with Serum VEGFR2 and Pharmacodynamics of Pazopanib
  Michael L. Maitland, Chun-Fang Xu, Yu-Ching Cheng, Emily Kistner-Griffin, Kathleen A. Ryan, Theodore Karrison, Soma Das, Dara G. Torgerson, Eric R. Gamazon, Vasiliki T...> ;Clinical Cancer Research. 2015 Jan 15
• Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
  Federico Innocenti, Richard L. Schilsky, Jacqueline Ramírez, Linda Janisch, Samir D. Undevia, Larry House, Soma Das, Kehua Wu, Michelle Turcich, Robert de Wilton Marsh...> ;Journal of Clinical Oncology. 2014 Aug 1
• Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies
  Sanja Karovic, Yujia Wen, Theodore Karrison, George L. Bakris, Matthew R. Levine, Larry House, Kehua Wu, Vasiliki Thomeas, Michelle A. Rudek, John Wright, Ezra E.W. Co...> ;Clinical Pharmacology & Therapeutics. 2014 Jul 1
• Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.
  Vasiliki Thomeas, Selina Chow, Jose O. Gutierrez, Sanja Karovic, Kristen Wroblewski, Emily Kistner-Griffin, Theodore Karrison, Michael L. Maitland> ;The Journal of Clinical Pharmacology. 2014 Jun 1
• 4 citations
  Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously trea...
  Michael L. Maitland, Matthew R. Levine, Mario E. Lacouture, Kristen Wroblewski, Christine H. Chung, Ilyssa O. Gordon, Livia Szeto, Gail Ratko, Keyoumars Soltani, Mark ...> ;BMC Cancer. 2014 Jan 4
• 3 citations
  Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science
  M. Eileen Dolan, Michael L. Maitland, Peter H. O'Donnell, Yusuke Nakamura, Nancy J. Cox, Mark J. Ratain> ;Pharmacogenomics. 2013 Sep 11
• Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients
  Manish Sharma, Theodore Karrison, Bethany Kell, Kehua Wu, Michelle Turcich, David Geary, Soonmo Peter Kang, Naoko Takebe, Richard A. Graham, Michael L. Maitland, Richa...> ;Clinical Cancer Research. 2013 Jun 1
• 6 citations
  Time to tumor growth: a model end point and new metric system for oncology clinical trials.
  Maitland, M. L., Schwartz, L. H., Ratain, M. J.> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 May 8
• Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling
  Michael L. Maitland, Kehua Wu, Manish Sharma, Yuyan Jin, Soonmo Peter Kang, Walter M. Stadler, Theodore Karrison, Mark J. Ratain, Robert R. Bies> ;Clinical Pharmacology & Therapeutics. 2013 Apr 1
• Join now to see all